{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:29:20Z","timestamp":1791066560388,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eliminating alloreactive cells from T-cell populations would enable the transfer of immune function to patients who receive stem cell transplants. However, high-efficiency depletion has proved difficult to achieve. We sought to develop ex vivo approaches for the maximal depletion of alloreactive CD4+ T cells. Using a flow cytometric cell sorting approach after mixed lymphocyte reaction (MLR) culture, we have found that sorted CFSEbright (5-(and-6)-carboxyfluorescein diacetate succinmidyl ester) (nondivided) and activation antigen-negative cells are markedly depleted of alloreactivity. With HLA-mismatched peripheral blood mononuclear cell (PBMC) stimulators we have consistently attained (90%-95%) depletion of alloreactivity. Importantly, when purified matured monocyte-derived dendritic cells (DCs) are used as stimulators, a 100-fold (99%) reduction in alloreactivity was attained, resulting in abrogation of the secondary MLR. Significantly, the CFSEbright CD25- cells recovered from these cultures retained general immunoreactivity, including responses to Candida and cytomegalovirus (CMV) antigens. In addition, a CFSE-based approach was tested and found to be sufficient for graft-versus-host disease (GVHD) prevention in vivo, in a major histocompatibility complex (MHC) class II disparate murine model. This efficient approach to selectively deplete mature alloantigen-specific T cells may permit enhanced immune reconstitution without GVHD. (Blood. 2004;103:1158-1165)<\/jats:p>","DOI":"10.1182\/blood-2003-04-1098","type":"journal-article","created":{"date-parts":[[2003,10,7]],"date-time":"2003-10-07T00:16:34Z","timestamp":1065485794000},"page":"1158-1165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation"],"prefix":"10.1182","volume":"103","author":[{"given":"Wayne R.","family":"Godfrey","sequence":"first","affiliation":[{"name":"From the Departments of Pediatrics and Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Krampf","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300064622000_REF1","doi-asserted-by":"crossref","unstructured":"Martelli MF, Aversa F, Bachar-Lustig E, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39: 48-56.","DOI":"10.1053\/shem.2002.29255"},{"key":"2020021300064622000_","doi-asserted-by":"crossref","unstructured":"Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92: 3515-3520.","DOI":"10.1182\/blood.V92.10.3515"},{"key":"2020021300064622000_REF3","doi-asserted-by":"crossref","unstructured":"Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev. 1997;157: 79-109.","DOI":"10.1111\/j.1600-065X.1997.tb00976.x"},{"key":"2020021300064622000_REF4","doi-asserted-by":"crossref","unstructured":"Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol. 2002;39: 15-22.","DOI":"10.1053\/shem.2002.29246"},{"key":"2020021300064622000_REF5","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey-Abina S, Bensoussan D, Le Deist F, Fischer A. Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol. 2002;39: 32-40.","DOI":"10.1053\/shem.2002.29251"},{"key":"2020021300064622000_REF6","doi-asserted-by":"crossref","unstructured":"Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98: 3192-3204.","DOI":"10.1182\/blood.V98.12.3192"},{"key":"2020021300064622000_REF7","unstructured":"Wagner JE, Thompson JS, Carter S, Jensen L, Kernan NA. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS): results of a multi-center, randomized phase II-III trial comparing T-cell depletion\/cyclosporine (TCD) and methotrexate\/cyclosporine (M\/C) in 410 recipients of unrelated donor bone marrow (BM) [abstract]. Blood. 2002;100: 274a."},{"key":"2020021300064622000_REF8","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive T-cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50: 1-7.","DOI":"10.1097\/00007890-199007000-00001"},{"key":"2020021300064622000_","doi-asserted-by":"crossref","unstructured":"Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T-cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998;101: 565-570.","DOI":"10.1046\/j.1365-2141.1998.00748.x"},{"key":"2020021300064622000_REF10","doi-asserted-by":"crossref","unstructured":"Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T-cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93: 3550-3557.","DOI":"10.1182\/blood.V93.10.3550.410k24_3550_3557"},{"key":"2020021300064622000_REF11","doi-asserted-by":"crossref","unstructured":"Garderet L, Snell V, Przepiorka D, et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999;67: 124-130.","DOI":"10.1097\/00007890-199901150-00021"},{"key":"2020021300064622000_","doi-asserted-by":"crossref","unstructured":"Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23: 1071-1079.","DOI":"10.1038\/sj.bmt.1701749"},{"key":"2020021300064622000_","doi-asserted-by":"crossref","unstructured":"van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T-cells: towards prevention of acute graft-versus-host disease. Br J Haematol. 1999;107: 169-175.","DOI":"10.1046\/j.1365-2141.1999.01675.x"},{"key":"2020021300064622000_REF14","doi-asserted-by":"crossref","unstructured":"Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol. 2000;109: 644-651.","DOI":"10.1046\/j.1365-2141.2000.02074.x"},{"key":"2020021300064622000_REF15","unstructured":"Rencher SD, Houston JA, Lockey TD, Hurwitz JL. Eliminating graft-versus-host potential from T-cell immunotherapeutic populations. Bone Marrow Transplant. 1996;18: 415-420."},{"key":"2020021300064622000_REF16","doi-asserted-by":"crossref","unstructured":"Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood. 2002;99: 3041-3049.","DOI":"10.1182\/blood.V99.8.3041"},{"key":"2020021300064622000_REF17","doi-asserted-by":"crossref","unstructured":"Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T-cells by photodynamic cell purging process. Blood. 2002;99: 3083-3088.","DOI":"10.1182\/blood.V99.9.3083"},{"key":"2020021300064622000_REF18","doi-asserted-by":"crossref","unstructured":"Michalek J, Collins RH, Durrani HP, et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T-cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A. 2003;100: 1180-1184.","DOI":"10.1073\/pnas.0337543100"},{"key":"2020021300064622000_REF19","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T-cells in an H-2 haplotype disparate mouse combination. Blood. 1994;83: 288-298.","DOI":"10.1182\/blood.V83.1.288.288"},{"key":"2020021300064622000_REF20","doi-asserted-by":"crossref","unstructured":"Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol. 2002;118: 108-116.","DOI":"10.1046\/j.1365-2141.2002.03682.x"},{"key":"2020021300064622000_REF21","doi-asserted-by":"crossref","unstructured":"Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1\/2 study. Lancet. 2002;360: 130-137.","DOI":"10.1016\/S0140-6736(02)09413-8"},{"key":"2020021300064622000_REF22","doi-asserted-by":"crossref","unstructured":"Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243: 147-154.","DOI":"10.1016\/S0022-1759(00)00231-3"},{"key":"2020021300064622000_REF23","doi-asserted-by":"crossref","unstructured":"Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T-cells in vivo: new answers to an old question. J Immunol. 2001;166: 973-981.","DOI":"10.4049\/jimmunol.166.2.973"},{"key":"2020021300064622000_REF24","doi-asserted-by":"crossref","unstructured":"Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179: 1109-1118.","DOI":"10.1084\/jem.179.4.1109"},{"key":"2020021300064622000_REF25","doi-asserted-by":"crossref","unstructured":"Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223: 1-15.","DOI":"10.1016\/S0022-1759(98)00208-7"},{"key":"2020021300064622000_REF26","doi-asserted-by":"crossref","unstructured":"Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med. 1999;189: 821-829.","DOI":"10.1084\/jem.189.5.821"},{"key":"2020021300064622000_REF27","doi-asserted-by":"crossref","unstructured":"Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50: 417-427.","DOI":"10.1007\/s002620100215"},{"key":"2020021300064622000_REF28","doi-asserted-by":"crossref","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413: 732-738.","DOI":"10.1038\/35099560"},{"key":"2020021300064622000_REF29","doi-asserted-by":"crossref","unstructured":"Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001;166: 249-255.","DOI":"10.4049\/jimmunol.166.1.249"},{"key":"2020021300064622000_REF30","doi-asserted-by":"crossref","unstructured":"Russell CA, Brondsted L, Vindelov LL. Design of limiting dilution analysis experiments for helper T lymphocyte precursor frequency determination in the context of allogeneic bone marrow transplantation. J Immunol Methods. 1999;225: 113-124.","DOI":"10.1016\/S0022-1759(99)00035-6"},{"key":"2020021300064622000_REF31","doi-asserted-by":"crossref","unstructured":"Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T-cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102: 473-482.","DOI":"10.1172\/JCI3741"},{"key":"2020021300064622000_REF32","doi-asserted-by":"crossref","unstructured":"Chang CH, Hong SC, Hughes CC, Janeway CA Jr, Flavell RA. CIITA activates the expression of MHC class II genes in mouse T cells. Int Immunol. 1995;7: 1515-1518.","DOI":"10.1093\/intimm\/7.9.1515"},{"key":"2020021300064622000_REF33","doi-asserted-by":"crossref","unstructured":"Otten LA, Tacchini-Cottier F, Lohoff M, et al. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes. J Immunol. 2003;170: 1150-1157.","DOI":"10.4049\/jimmunol.170.3.1150"},{"key":"2020021300064622000_REF34","doi-asserted-by":"crossref","unstructured":"Banchereau J, Briere F, Caux C. et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18: 767-811.","DOI":"10.1146\/annurev.immunol.18.1.767"},{"key":"2020021300064622000_REF35","doi-asserted-by":"crossref","unstructured":"Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor allo-reactive T-cells without loss of anti-viral or anti-leukemic responses. Blood. 2003;102: 2292-2299.","DOI":"10.1182\/blood-2002-11-3516"},{"key":"2020021300064622000_REF36","doi-asserted-by":"crossref","unstructured":"Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J Exp Med. 1998;188: 2357-2368.","DOI":"10.1084\/jem.188.12.2357"},{"key":"2020021300064622000_REF37","doi-asserted-by":"crossref","unstructured":"Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, Van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma -producing CD4+ T-cells in protection against CMV disease. Blood. 2003;101: 2686-2692.","DOI":"10.1182\/blood-2002-08-2502"},{"key":"2020021300064622000_REF38","doi-asserted-by":"crossref","unstructured":"O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lympho-proliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157: 195-216.","DOI":"10.1111\/j.1600-065X.1997.tb00983.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/1158\/1694930\/zh800304001158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/3\/1158\/1694930\/zh800304001158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T22:24:02Z","timestamp":1585175042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/3\/1158\/17244\/Ex-vivo-depletion-of-alloreactive-cells-based-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-04-1098","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}